# Trastuzumab Emtansine

## Kadcyla inj 100mg

##### 臨採

| TAH Drug Code      | [**IKAD1**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IKAD1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever, chills, or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Specific contraindications have not been determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Common ■Gastrointestinal: Constipation (26.5% ), Nausea (39.8% ) ■Hematologic: Thrombocytopenia, All grades (31.2% ) ■Hepatic: Increased liver enzymes, All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia, Grade 3 and 4 (4.1% ), Neutropenia, Grade 3 and 4 (2% ), Thrombocytopenia, Grade 3 and 4 (14.5% ) ■Hepatic: Hepatotoxicity, Increased liver enzymes, Grades 3 and 4 (8% ), Injury of liver ■Immunologic: Anaphylactoid reaction ■Neurologic: Peripheral nerve disease, Grade 3 or 4 (2.2% ) ■Respiratory: Dyspnea (12% ), Interstitial lung disease, Pneumonitis (0.8% to 1.2% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## KADCYLA inj 160mg

##### 臨採

| TAH Drug Code      | [**IKAD6**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IKAD6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Metastatic breast cancer, HER2 overexpression, monotherapy in patients who have received at least one prior trastuzumab and/or taxane therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.Do not administer KADCYLA at doses greater than 3.6 mg/kg. KADCYLA dose should not be re-escalated after a dose reduction is made. Do not substitute KADCYLA for or with trastuzumab. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for fever, chills, or other infusion related reactions. Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated. Patients should be observed during the infusion and for at least 30 minutes after infusion.                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Specific contraindications have not been determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Common ■Gastrointestinal: Constipation (26.5% ), Nausea (39.8% ) ■Hematologic: Thrombocytopenia, All grades (31.2% ) ■Hepatic: Increased liver enzymes, All grades (28.8% ) ■Musculoskeletal: Musculoskeletal pain (36.1% ) ■Neurologic: Headache (28.2% ) ■Other: Fatigue (36.3% ) Serious ■Cardiovascular: Left ventricular cardiac dysfunction (1.8% ) ■Dermatologic: Injection site extravasation ■Hematologic: Anemia, Grade 3 and 4 (4.1% ), Neutropenia, Grade 3 and 4 (2% ), Thrombocytopenia, Grade 3 and 4 (14.5% ) ■Hepatic: Hepatotoxicity, Increased liver enzymes, Grades 3 and 4 (8% ), Injury of liver ■Immunologic: Anaphylactoid reaction ■Neurologic: Peripheral nerve disease, Grade 3 or 4 (2.2% ) ■Respiratory: Dyspnea (12% ), Interstitial lung disease, Pneumonitis (0.8% to 1.2% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

